Henshaw highlighted that these results support the use of second-generation BTK inhibitors in frontline therapy and may help shape future NCCN guideline considerations. Real-world evidence evaluating the Triangle regimen is lacking, especially when utilizing second-generation BTK inhibitors such as acalabrutinib or zanubrutinib. The Triangle study specifically looked at the first-generation BTK inhibitor, ibrutinib, but we know in practice it is common to substitute with second-generation BTK inhibitors. When we evaluated the patients, we saw an equal distribution among all of the BTK inhibitors: 17 on ibrutinib and 15 on second-generation BTK inhibitors. Zanubrutinib and acalabrutinib, the second-generation BTK inhibitors, are only listed as category 2B.